{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:06:31Z","timestamp":1779098791366,"version":"3.51.4"},"reference-count":39,"publisher":"Impact Journals, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,10]]},"DOI":"10.18632\/oncotarget.13787","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T22:00:17Z","timestamp":1480975217000},"page":"3412-3421","source":"Crossref","is-referenced-by-count":23,"title":["The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with <i>EGFR<\/i> mutations"],"prefix":"10.18632","volume":"8","author":[{"given":"Jing-Hui","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital & Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014, Fujian Province, China"},{"name":"Group of Lung Cancer Treatment, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital & Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014, Fujian Province, China"},{"name":"Group of Lung Cancer Treatment, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital & Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014, Fujian Province, China"},{"name":"Group of Lung Cancer Treatment, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital & Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014, Fujian Province, China"},{"name":"Group of Lung Cancer Treatment, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hua","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital & Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014, Fujian Province, China"},{"name":"Group of Lung Cancer Treatment, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Peng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital & Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014, Fujian Province, China"},{"name":"Group of Lung Cancer Treatment, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Fujian Provincial Cancer Hospital & Cancer Hospital Affiliated to Fujian Medical University, Fuzhou 350014, Fujian Province, China"},{"name":"Group of Lung Cancer Treatment, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Jemal","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Lippman","year":"2008","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Haber","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.18632\/oncotarget.2925","article-title":"Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR","volume":"6","author":"Park","year":"2015","journal-title":"Oncotarget"},{"key":"5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/CCO.0000000000000163","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer","volume":"27","author":"Goss","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"68442","DOI":"10.18632\/oncotarget.12035","article-title":"Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations","volume":"7","author":"Han","year":"2016","journal-title":"Oncotarget"},{"key":"7","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","article-title":"Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer","volume":"16","author":"Pacey","year":"2015","journal-title":"Lancet Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","article-title":"Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis","volume":"33","author":"Yang","year":"2015","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.2014-0285","article-title":"The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials","volume":"20","author":"Ou","year":"2015","journal-title":"Oncologist"},{"key":"10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Yang","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"11","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Mok","year":"2011","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"You","year":"2011","journal-title":"Lancet Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Fukuoka","year":"2010","journal-title":"Lancet Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/CCO.0000000000000164","article-title":"Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer","volume":"27","author":"Yang","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2005.00.992","article-title":"Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence","volume":"23","author":"Yatabe","year":"2005","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"e107161","DOI":"10.1371\/journal.pone.0107161","article-title":"Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Settleman","year":"2004","journal-title":"Science"},{"key":"19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00280-014-2631-5","article-title":"EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation","volume":"75","author":"Kim","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Felip, Gridelli, Baas, Rosell, Stahel. Panel Members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. 1st ESMO Consensus Conference in Lung Cancer. Lugano. 2010. Ann Oncol. 2011; 22:pp. 1507\u20131519.","DOI":"10.1093\/annonc\/mdr150"},{"key":"21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.2012.43.0652","article-title":"Treating patients with EGFR-sensitizing mutations: first line or second line\u2014is there a difference?","volume":"31","author":"Lam","year":"2013","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000187427","article-title":"Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting\u2014does it matter? A single-institution experience","volume":"76","author":"Ramnath","year":"2009","journal-title":"Oncology"},{"key":"23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3816\/CLC.2008.n.037","article-title":"An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin\/gemcitabine versus first-line cisplatin\/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial","volume":"9","author":"Perrone","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial","volume":"30","author":"Perrone","year":"2012","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.lungcan.2012.03.010","article-title":"Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study","volume":"77","author":"Gatzemeier","year":"2012","journal-title":"Lung Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/clpt.2009.64","article-title":"Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development","volume":"86","author":"Gobburu","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"27","first-page":"143","article-title":"Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)","volume":"32","author":"Wang","year":"2010","journal-title":"Chin J Oncol"},{"key":"28","first-page":"419","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Mehta","year":"2012","journal-title":"JClinOncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11523-015-0358-9","article-title":"Gefitinib: a review of its use in adults with advanced non-small cell lung cancer","volume":"10","author":"Dhillon","year":"2015","journal-title":"Target Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Haber","year":"2004","journal-title":"N Engl J Med"},{"key":"31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00280-007-0616-3","article-title":"The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates","volume":"62","author":"Balis","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"32","first-page":"413","article-title":"Best supportive care in lung cancer - do we know what it is?","volume":"22","author":"Jack","year":"2008","journal-title":"Palliat Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.athoracsur.2015.07.031","article-title":"Long-term effect of an interdisciplinary supportive care intervention for lung cancer survivors after surgical procedures","volume":"101","author":"Ferrell","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1590\/S0041-87812001000200004","article-title":"Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain","volume":"56","author":"Fogarolli","year":"2001","journal-title":"Rev Hosp Clin Fac Med Sao Paulo"},{"key":"35","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/bjc.2011.179","article-title":"A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer","volume":"104","author":"Wiezorek","year":"2011","journal-title":"Br J Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1634\/theoncologist.2009-0054","article-title":"The role of EGFR inhibition in the treatment of non-small cell lung cancer","volume":"14","author":"Vokes","year":"2009","journal-title":"Oncologist"},{"key":"37","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3892\/or.2013.2709","article-title":"Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer","volume":"30","author":"Bi","year":"2013","journal-title":"Oncol Rep"},{"key":"38","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.rmed.2010.08.005","article-title":"Staging of non-small cell lung cancer (NSCLC): a review","volume":"104","author":"Davidson","year":"2010","journal-title":"Respir Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2013.52.3019","article-title":"Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse","volume":"32","author":"Sargent","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T14:00:26Z","timestamp":1589119226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1,10]]}},"alternative-id":["13787","27926500"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13787","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,3]]}}}